Hi Montrachet & Singhgu,
I did post recently on a conference presentation for REMAP-CAP & they had recently published a summary of treatments investigated.
Interestingly, DMX-200/ARB is not one of them at present & it does make you wonder if they are maybe looking at longer term follow-up with BIG issues of Long COVID now & DMX-200 as an anti-inflammatory, anti-fibrotic drug for the lungs & other organs before publishing?
I agree it has been a LONG time & if it were quick & simple to say % of patients in primary & secondary endpoints with both moderate & severe disease, that would have been disseminated by now.
Maybe it’s not? IDK, intriguing for a platform trial to be taking so long on such a burning question with ARB/ACEi + DMX-200 in this REMAP-CAP Domain.
Ann: REMAP-CAP COVID-19 Study Analysis Update, page-51
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $206.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |